Year: 2021

annonceHomeUS

TG4050First positive data from Phase I clinical trials Press release [PDF] Initial data presented at the ASCO congress (June 2022) Interview of the team and Pr Ottensmeier on the data (November 2022)

Regulated information

Monthly information on shares outstanding and voting rights (in French) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Share buyback program (in French) Descriptif du programme de rachat d’actions autorisé par l’assemblée générale mixte des actionnaires du 24 mai 2016 Liquidity contract related information Implementation of the liquidity agreement Half-year report on… Continue reading Regulated information

aacr

AACR 2024 Transgene et NEC Present Proof of Principle Data for TG4050 in Head & Neck Cancer Donwload Press release (PDF) Interview of Alessandro Riva Donwload the Poster (PDF)

annonce substitut

A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s tumor. TG4050 video

annonce

One cancer, one patient, one vaccine With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies. The treatment is based on an optimized MVA viral vector. myvac® video Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens)… Continue reading annonce